{"id":12140,"date":"2023-11-02T22:39:00","date_gmt":"2023-11-02T14:39:00","guid":{"rendered":"https:\/\/flcube.com\/?p=12140"},"modified":"2024-11-11T22:46:22","modified_gmt":"2024-11-11T14:46:22","slug":"epimah-biotherapeutics-to-present-first-in-human-results-for-emb-06-at-sitc-annual-meeting","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12140","title":{"rendered":"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting"},"content":{"rendered":"\n

Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its pipeline candidate EMB-06, a BCMAxCD3 bispecific antibody (BsAb), at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in California. The late-breaker poster presentation will detail initial safety, efficacy, and pharmacokinetic\/pharmacodynamic (PK\/PD) data from the Phase I dose escalation stage of a Phase I\/II study in patients with relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).<\/p>\n\n\n\n

EMB-06 Development and Platform<\/strong>
Developed on EpimAb’s proprietary CD3 panel and bispecific platforms, EMB-06 is an innovative 2+2 BCMA\u00d7CD3 T-cell engaging BsAb. EpimAb has stated that this BsAb has demonstrated lower levels of cytokine release in both preclinical and clinical studies, marking a significant advancement in the field of immunotherapy.<\/p>\n\n\n\n

Initial Data and Platform Capabilities<\/strong>
The initial data from the study is viewed by the Shanghai firm as indicative of its BsAb platform and CD3 panel capabilities. These capabilities enable the targeting of tumor antigens while reducing the risk of cytokine release and neurotoxicity, which are critical considerations in the development of effective and safe immunotherapies.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[268],"class_list":["post-12140","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-epimab-biotherapeutics"],"yoast_head":"\nEpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its pipeline candidate EMB-06, a BCMAxCD3 bispecific antibody (BsAb), at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in California. The late-breaker poster presentation will detail initial safety, efficacy, and pharmacokinetic\/pharmacodynamic (PK\/PD) data from the Phase I dose escalation stage of a Phase I\/II study in patients with relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12140\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12140\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-02T14:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-11T14:46:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12140#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12140\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting\",\"datePublished\":\"2023-11-02T14:39:00+00:00\",\"dateModified\":\"2024-11-11T14:46:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12140\"},\"wordCount\":196,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"EpimAb Biotherapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12140#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12140\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12140\",\"name\":\"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-02T14:39:00+00:00\",\"dateModified\":\"2024-11-11T14:46:22+00:00\",\"description\":\"Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its pipeline candidate EMB-06, a BCMAxCD3 bispecific antibody (BsAb), at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in California. The late-breaker poster presentation will detail initial safety, efficacy, and pharmacokinetic\\\/pharmacodynamic (PK\\\/PD) data from the Phase I dose escalation stage of a Phase I\\\/II study in patients with relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12140#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12140\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12140#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting - Insight, China's Pharmaceutical Industry","description":"Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its pipeline candidate EMB-06, a BCMAxCD3 bispecific antibody (BsAb), at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in California. The late-breaker poster presentation will detail initial safety, efficacy, and pharmacokinetic\/pharmacodynamic (PK\/PD) data from the Phase I dose escalation stage of a Phase I\/II study in patients with relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12140","og_locale":"en_US","og_type":"article","og_title":"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12140","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-02T14:39:00+00:00","article_modified_time":"2024-11-11T14:46:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12140#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12140"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting","datePublished":"2023-11-02T14:39:00+00:00","dateModified":"2024-11-11T14:46:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12140"},"wordCount":196,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["EpimAb Biotherapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12140#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12140","url":"https:\/\/flcube.com\/?p=12140","name":"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-02T14:39:00+00:00","dateModified":"2024-11-11T14:46:22+00:00","description":"Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its pipeline candidate EMB-06, a BCMAxCD3 bispecific antibody (BsAb), at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in California. The late-breaker poster presentation will detail initial safety, efficacy, and pharmacokinetic\/pharmacodynamic (PK\/PD) data from the Phase I dose escalation stage of a Phase I\/II study in patients with relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12140#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12140"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12140#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12140"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12140\/revisions"}],"predecessor-version":[{"id":12142,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12140\/revisions\/12142"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}